1-4 of 4
Kristin M. Zimmerman Savill
Close
Sort by
Journal Articles

Tafasitamab for the Treatment of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) in the US Real-World Setting

Kimberly Saverno, Kristin M. Zimmerman Savill, Bruce Feinberg, John Galvin, Prathamesh Pathak, Sarah Gordon, Theresa Amoloja, Mae Llorente, Narendranath Epperla, Loretta J. Nastoupil
Journal: Blood
Blood (2023) 142 (Supplement 1): 265.
https://doi.org/10.1182/blood-2023-173143
Published: 2023
Journal Articles

Real-World Use of Tafasitamab (tafa) for Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Among Racial and Ethnic Minorities in the United States

Narendranath Epperla, Loretta J. Nastoupil, Kristin M. Zimmerman Savill, Bruce Feinberg, John Galvin, Prathamesh Pathak, Sarah Gordon, Theresa Amoloja, Mae Llorente, Kimberly Saverno
Journal: Blood
Blood (2023) 142 (Supplement 1): 2415.
https://doi.org/10.1182/blood-2023-173456
Published: 2023
Journal Articles

Real-World Treatment of Patients with Large B-Cell Lymphoma in the United States with Chimeric Antigen Receptor T-Cell Therapy

Kristin M. Zimmerman Savill, Andrew J Klink, Djibril Liassou, Dhruv Chopra, Jalyna Laney, Ajeet Gajra
Journal: Blood
Blood (2021) 138 (Supplement 1): 4096.
https://doi.org/10.1182/blood-2021-150723
Published: 2021
Journal Articles

Lower-Risk Myelodysplastic Syndromes: Erythropoiesis-Stimulating Agent Treatment Approaches and Outcomes in the United States

Kristin M. Zimmerman Savill, Ajeet Gajra, Kwanza Price, Jonathan K. Kish, Cherrishe Brown-Bickerstaff, Angelica Falkenstein, Talia Miller, JaLyna Laney, Sudipto Mukherjee
Journal: Blood
Blood (2021) 138 (Supplement 1): 4657.
https://doi.org/10.1182/blood-2021-146461
Published: 2021